Samples collected from myeloma patients at first relapse registered into the Myeloma XII trial, and sent to the following central labs: 1. Central immunology laboratory, University of Birmingham - pe
CR, complete response; ISS, International Staging System; NE, not evaluable; PD, progressive disease; SD, stable disease; VGPR, very good partial response. *Excluded were three patients not evaluable
CN: Myeloma Cast Nephropathy;LCDD: Light Chain Deposition Disease; MM: Multiple Myeloma; AKI: acute kidney injury. Values are mean ±SD or median (range)* 1 subject had two distinct episodes of AKIOne
Objective: To present a descriptive analysis of patients diagnosed with multiple myeloma, correlating it with mortality. Methods: A retrospective study that analyzed consecutive patients diagnosed wit